Process in the mechanisms of endostatin combined with radiotherapy

Cancer Letters

Volumn 282, Issue 1, 2009, Pages 9-13

  Zhuang, Hong Qing ^a,b   Yuan, Zhi Yong ^a,b  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b Tianjin Lung Cancer Center   (China)

Author keywords

Angiogenesis; Anti angiogenic therapies; Endostatin; Radiotherapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ENDOSTATIN; GELATINASE A; INTERLEUKIN 8; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; BLOOD VESSEL INJURY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; CYTOTOXICITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; ENDOTHELIUM; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MENSTRUATION DISORDER; MOLECULAR MIMICRY; MONOTHERAPY; OXYGENATION; PHARMACOGENETICS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SHORT SURVEY; SKIN INJURY; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

EID: 67649413175     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.12.008     Document Type: Review

References (76)

1. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 285 (1971) 1182-1186
2. Folkman J. Tumor angiogenesis and tissue factor. Nat. Med. 2 (1996) 167-168
3. Auerbach W., and Auerbach R. Angiogenesis inhibition: a review. Pharmacol. Therapeut. 63 (1994) 265-311
4. Winlaw D.S. Angiogenesis in the pathobiology and treatment of vascular and malignant diseases. Ann. Thorac. Surg. 64 (1997) 1204-1211
5. Folkman J. Is angiogenesis an organizing principle in biology and medicine?. J. Pediatr. Surg. 42 (2007) 1-11
6. Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp. Cell Res. 312 (2006) 594-607
7. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov. 6 (2007) 273-286
8. Michael S.O. Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int. J. Radiat. Oncol. Biol. Phys. 69 (2007) S64-S66
9. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
10. Blezinger P., Wang J., Gondo M., Quezada A., Mehrens D., French M., Singhal A., Sullivan S., Rolland A., Ralston R., and Min W. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 17 (1999) 343-348
11. Herbst R.S., Lee A.T., Tran H.T., and Abbruzzese J.L. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial Of Human Endostatin. Curr. Oncol. Rep. 3 (2001) 131-140
12. Oh S.P., Warman M.L., Seldin M.F., Cheng S.D., Knoll J.H., Timmons S., and Olsen B.R. Cloning of cDNA and genomic DNA encoding human type XVIII collagen and localization of the alpha 1(XVIII) collagen gene to mouse chromosome 10 and human chromosome 21. Genomics 19 (1994) 494-499
13. Abdollahi A., Hahnfeldt P., Maercker C., Grone H.J., Debus J., Ansorge W., Folkman J., Hlatky L., and Huber P.E. Endostatin's antiangiogenic signaling network. Mol. Cell. 13 (2004) 649-663
14. Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv. Cancer Res. 100 (2008) 113-131
15. Burri P.H., Hlushchuk R., and Djonov V. Intussusceptive angiogenesis: it s emergence, it s characteristics, and its significance. Dev. Dyn. 231 (2004) 474-488
16. Folberg R., and Maniotis A.J. Vasculogenic mimicry. APMIS 12 (2004) 508-525
17. Rüegg C., Meuwly J.Y., Driscoll R., Werffeli P., Zaman K., and Stupp R. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr. Mol. Med. 3 (2003) 673-691
18. Boehm T., Folkman J., Browder T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390 (1997) 404-407
19. Drevs J., Laus C., Medinger M., Schmidt-Gersbach C., and Unger C. Antiangiogenesis: current clinical data and future perspectives. Onkologie 25 (2002) 520-527
20. Kerbel R.S., Yu J., Tran J., Man S., Viloria-Petit A., Klement G., Coomber B.L., and Rak J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metast Rev. 20 (2001) 79-86
21. Yu J.L., Rak J.W., Coomber B.L., Hicklin D.J., and Kerbel R.S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295 (2002) 1526-1528
22. Richard D.E., Berra E., and Pouyssegur J. Angiogenesis: how a tumor adapts to hypoxia. Biochem. Biophys. Res. Commun. 266 (1999) 718-722
23. Lou J., He J., Jin L., Zheng W., Wang B., and Deng H. Measuring the genetic damage in cancer patients during radiotherapy with three genetic end-points. Mutagenesis 19 (2004) 457-464
24. Lindsay K.A., Wheldon E.G., Deehan C., and Wheldon T.E. Radiation carcinogenesis modelling for risk of treatment-related second tumours following radiotherapy. Br. J. Radiol. 74 (2001) 529-536
25. McIlwrath A.J., Vasey P.A., Ross G.M., and Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res. 54 (1994) 3718-3722
26. Williams J.R., Zhang Y., Zhou H., Russell J., Gridley D.S., Koch C.J., and Little J.B. Genotype-dependent radiosensitivity: clonogenic survival, apoptosis and cell-cycle redistribution. Int. J. Radiat. Biol. 84 (2008) 151-164
27. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., Seetharam S., Koons A., Hari D.M., Kufe D.W., and Weichselbaum R.R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59 (1999) 3374-3378
28. Koukourakis M.I., Giatromanolaki A., Sivridis E., Simopoulos K., Pissakas G., Gatter K.C., and Harris A.L. Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy. Anticancer Res. 21 (2001) 4301-4309
29. Katoh O., Tauchi H., Kawaishi K., Kimura A., and Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55 (1995) 5687-5692
30. Gupta V.K., Jaskowiak N.T., Beckett M.A., Mauceri H.J., Grunstein J., Johnson R.S., Calvin D.A., Nodzenski E., Pejovic M., Kufe D.W., Posner M.C., and Weichselbaum R.R. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 8 (2002) 47-54
31. Kumar P., Miller A.I., and Polverini P.J. P38 MAPK mediates-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J. Biol. Chem. 279 (2004) 43352-43360
32. Itasaka S., Komaki R., Herbst R.S., Shibuya K., Shintani T., Hunter N.R., Onn A., Bucana C.D., Milas L., Ang K.K., and O'Reilly M.S. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 870-878
33. Luo X., Andres M.L., Timiryasova T.M., Fodor I., Slater J.M., and Gridley D.S. Radiation-enhanced endostatin gene expression and effects of combination treatment. Technol. Cancer. Res. Treat. 4 (2005) 193-201
34. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., and McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156 (2000) 1363-1380
35. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., and McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160 (2002) 985-1000
36. Jain R.K., Munn L.L., and Fukumura D. Dissecting tumor pathophysiology using intravital microscopy. Nat. Rev. Cancer. 2 (2002) 266-276
37. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 48 (1988) 2641-2658
38. Tufto I., and Rofstad E.K. Transient perfusion in human melanoma xenografts. Br. J. Cancer 71 (1995) 789-793
39. Durand R.E., and LePard N.E. Contribution of transient blood flow to tumour hypoxia in mice. Acta. Oncol. 34 (1995) 317-323
40. Chaplin D.J., Olive P.L., and Durand R.E. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res. 47 (1987) 597-601
41. Chaplin D.J., Durand R.E., and Olive P.L. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int. J. Radiat. Oncol. Biol. Phys. 2 (1986) 1279-1282
42. Bussink J., Kaanders J.H., and van der Kogel A.J. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother. Oncol. 67 (2003) 3-15
43. Cousins C., and Sharp C. Medical interventional procedures-reducing the radiation risks. Clin. Radiol. 59 (2004) 468-473
44. Teicher B.A., Holden S.A., Ara G., Dupuis N.P., Liu F., Yuan J., Ikebe M., and Kakeji Y. Impudence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int. J. Cancer 61 (1995) 732-737
45. Lee C.G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., Park K.R., Ferrara N., Jain R.K., Suit H.D., and Boucher Y. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60 (2000) 5565-5570
46. Griffin R.J., Williams B.W., Wild R., Cherrington J.M., Park H., and Song C.W. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 62 (2002) 1702-1706
47. Teicher B.A., Holden S.A., Ara G., Sotomayor E.A., Huang Z.D., Chen Y.N., and Brem H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer. 57 (1994) 920-925
48. Wachsberger P., Burd R., and Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9 (2003) 1957-1971
49. O'Reilly M.S., Holmgren L., Chen C., and Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2 (1996) 689-692
50. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7 (2001) 987-989
51. Tong R.T., Boucher Y., Kozin S.V., Winkler F., Hicklin D.J., and Jain R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64 (2004) 3731-3736
52. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., and Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 93 (1996) 14765-14770
53. Folkman J., and Camphausen K. Cancer: what does radiotherapy do to endothelial cells?. Science 293 (2001) 227-228
54. Geng L., Donnelly E., McMahon G., Lin P.C., Sierra-Rivera E., Oshinka H., and Hallahan D.E. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 61 (2001) 2413-2419
55. Shaheen R.M., Tseng W.W., Davis D.W., Liu W., Reinmuth N., Vellagas R., Wieczorek A.A., Ogura Y., McConkey D.J., Drazan K.E., Bucana C.D., McMahon G., and Ellis L.M. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res. 61 (2001) 1464-1468
56. Citrin D., Ménard C., and Camphausen K. Combining radiotherapy and angiogenesis inhibitors: clinical trial design. Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 15-25
57. Folkman J., and Ingber D. Inhibition of angiogenesis. Semin. Cancer Biol. 3 (1992) 89-96
58. Tannock I.F. Tumor physiology and drug resistance, cancer metast. Review 20 (2001) 123-132
59. Kuenen B.C., Rosen L., Smit E.F., Parson M.R., Levi M., Ruijter R., Huisman H., Kedde M.A., Noordhuis P., van der Vijgh W.J., Peters G.J., Cropp G.F., Scigalla P., Hoekman K., Pinedo H.M., and Giaccone G. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20 (2002) 1657-1667
60. Marx G.M., Steer C.B., Harper P., Pavlakis N., Rixe O., and Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!. J. Clin. Oncol. 20 (2002) 1446-1448
61. Kisker O., Becker C.M., Prox D., Fannon M., D'Amato R., Flynn E., Fogler W.E., Sim B.K., Allred E.N., Pirie-Shepherd S.R., and Folkman J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61 (2001) 7669-7674
62. Petrangolini G., Pratesi G., De Cesare M., Supino R., Pisano C., Marcellini M., Giordano V., Laccabue D., Lanzi C., and Zunino F. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol. Cancer Res. 1 (2003) 863-870
63. Ergun A., Camphausen K., and Wein M. Optimal scheduling of radiotherapy and angiogenic inhibitors. Bull. Math. Biol. 65 (2003) 407-424
64. Hilmas D.E., and Gillette E.L. Tumor microvasculature following fractionated X irradiation. Radiology 116 (1975) 165-169
65. Zhang S., Guo H., Zhang D., Zhang W., Zhao X., Ren Z., and Sun B. Microcirculation patterns in different stages of melanoma growth. Oncol. Rep. 15 (2006) 15-20
66. Cosgrove D. Angiogenesis imaging-Ultrasound. Br. J. Radiol. 76 (2003) S43-S49
67. Forsberg F., Ro R.J., Potoczek M., Liu J.B., Merritt C.R., James K.M., Dicker A.P., and Nazarian L.N. Assessment of angiogenesis: implications for ultrasound imaging. Ultrasonics 42 (2004) 325-330
68. Kothari M., Guermazi A., White D., Suhy J., and Reinhold C. Imaging in antiangiogenesis trial: a clinical trials radiology perspective. Br. J. Radiol. 76 (2003) S92-S96
69. Schirner M., Menrad A., Stephens A., Frenzel T., Hauff P., and Licha K. Molecular imaging of tumor angiogenesis. Ann. NY Acad. Sci. 1014 (2004) 67-75
70. Padhani A.R. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J. Magn. Reson. Imaging 16 (2002) 407-422
71. Choyke P., Dwyer A., and Knopp M. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 17 (2003) 509-520
72. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004) 423-436
73. Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol. 2 (2001) 733-740
74. Browder T., Butterfield C.E., Kräling B.M., Shi B., Marshall B., O'Reilly M.S., and Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60 (2000) 1878-1886
75. O'Reilly M.S. Radiation combined with antiangiogenic and antivascular agents. Seminars Radiat. Oncol. 16 (2006) 45-50
76. Bello L., Carrabba G., Giussani C., Lucini V., Cerutti F., Scaglione F., Landré J., Pluderi M., Tomei G., Villani R., Carroll R.S., Black P.M., and Bikfalvi A. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 61 (2001) 7501-7506